Interdisciplinary Centre for Health Studies (CIESAL), Cochrane Chile Associate Centre, Universidad de Valparaíso, Viña del Mar, Chile.
School of Medicine, Universidad de Valparaíso, Viña del Mar, Chile.
BMJ Evid Based Med. 2023 Aug;28(4):273-282. doi: 10.1136/bmjebm-2021-111811. Epub 2022 Feb 25.
To assess the effectiveness of non-pharmacological interventions for the treatment of autism spectrum disorder (ASD) in children.
Overview of systematic reviews (SRs).
Children aged 12 years and under with ASD.
In October 2021, we searched Cochrane Central Register of Controlled Trials, MEDLINE, Embase, PsycINFO and Epistemonikos placing no restrictions on language or date of publication.
17 non-pharmacological interventions compared with placebo, no-treatment (including waiting list) or other interventions (ie, usual care, as defined by the authors of each study).
We rated the methodological quality of the included SRs using A Measurement Tool to Assess Systematic Reviews (AMSTAR 2). We reported the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) certainty of the evidence (CoE) according to the analysis conducted by the authors of the included SRs.
A multidisciplinary group of experts agreed on analysing nine critical outcomes evolving core and non-core ASD symptoms.
Organisations of parents of children with ASD participated in external revision of the final version of the report.
We identified 52 reports that were within our scope, of which 48 were excluded for various reasons. After excluding less reliable SRs, we included four SRs. Non-pharmacological interventions (ie, Early Intensive Behavioural Intervention, Applied Behaviour Analysis, Picture Exchange Communication System and Naturalistic Developmental Behavioural Interventions) may have favourable effects on some core outcomes including language, social and functioning, play or daily living skills in children with ASD (with either no GRADE assessment, very low or low CoE). In addition, we identified a lack of report for other key outcomes in the included SRs (ie, restricted, repetitive behaviour; play and sensory processing).
Synthesised evidence regarding the efficacy of non-pharmacological interventions for children with ASD is scarce. High-quality SRs addressing the variety of both non-pharmacological interventions and relevant outcomes are needed.
CRD42020206535.
评估非药物干预治疗儿童自闭症谱系障碍(ASD)的疗效。
系统评价概述。
年龄在 12 岁及以下的 ASD 儿童。
2021 年 10 月,我们对 Cochrane 对照试验中心注册库、MEDLINE、Embase、PsycINFO 和 Epistemonikos 进行了检索,未对语言或发表日期进行限制。
17 种非药物干预措施与安慰剂、无治疗(包括等待名单)或其他干预措施(即作者定义的常规护理)进行比较。
我们使用评估系统评价的测量工具(AMSTAR 2)对纳入的系统评价的方法学质量进行了评分。我们根据纳入的系统评价作者进行的分析,报告了推荐、评估、制定和评价分级(GRADE)证据的确定性(CoE)。
一组多学科专家同意分析九个关键结果,这些结果涉及核心和非核心 ASD 症状。
ASD 儿童的家长组织参与了报告最终版本的外部修订。
我们确定了 52 份符合我们研究范围的报告,其中 48 份因各种原因被排除在外。在排除了不太可靠的系统评价后,我们纳入了四项系统评价。非药物干预措施(即早期密集行为干预、应用行为分析、图片交换沟通系统和自然发展行为干预)可能对一些核心结果产生有利影响,包括 ASD 儿童的语言、社交和功能、游戏或日常生活技能(没有 GRADE 评估、极低或低 CoE)。此外,我们还发现纳入的系统评价中缺乏其他关键结果的报告(即受限、重复行为;游戏和感觉处理)。
关于非药物干预治疗 ASD 儿童疗效的综合证据很少。需要高质量的系统评价来解决各种非药物干预措施和相关结果。
PROSPERO 注册号:CRD42020206535。